# Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

> **NCT03323398** · PHASE1,PHASE2 · TERMINATED · sponsor: **ModernaTX, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** mRNA-2416
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03323398
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-15
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03323398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03323398, "Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03323398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*